The Patent Trial and Appeal Board has instituted four of the Coalition for Affordable Drugs’ IPR petitions challenging Celgene patents, bringing the total number its petitions instituted to seven and greatly shifting the success rate of what one law firm calls the “PTAB Crashers”
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Speaking to Managing IP at Via’s Bridge Summit in San Francisco, president Kevin Mack explains why the AI infrastructure boom is forcing a rethink of traditional SEP licensing and FRAND models
Law firms continue to sell clients on international footprints, but sprawling office networks count for little if financial structures discourage internal collaboration
A&O Shearman and Fish & Richardson invested in German talent, meanwhile, major firms have assembled for an on the merits case pitting KeeeX against OpenAI and Adobe